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Abstract
Background: Dengue has emerged as the most important vector-borne viral disease in tropical areas. Evaluations of the
burden and severity of dengue disease have been hindered by the frequent lack of laboratory confirmation and strong
selection bias toward more severe cases.
Methodology: A multinational, prospective clinical study was carried out in South-East Asia (SEA) and Latin America (LA), to
ascertain the proportion of inapparent dengue infections in households of febrile dengue cases, and to compare clinical
data and biological markers from subjects with various dengue disease patterns. Dengue infection was laboratory-
confirmed during the acute phase, by virus isolation and detection of the genome. The four participating reference
laboratories used standardized methods.
Principal Findings: Among 215 febrile dengue subjects—114 in SEA and 101 in LA—28 (13.0%) were diagnosed with severe
dengue (from SEA only) using the WHO definition. Household investigations were carried out for 177 febrile subjects.
Among household members at the time of the first home visit, 39 acute dengue infections were detected of which 29 were
inapparent. A further 62 dengue cases were classified at early convalescent phase. Therefore, 101 dengue infections were
found among the 408 household members. Adding these together with the 177 Dengue Index Cases, the overall proportion
of dengue infections among the study participants was estimated at 47.5% (278/585; 95% CI 43.5–51.6). Lymphocyte counts
and detection of the NS1 antigen differed significantly between inapparent and symptomatic dengue subjects; among
inapparent cases lymphocyte counts were normal and only 20% were positive for NS1 antigen. Primary dengue infection
and a specific dengue virus serotype were not associated with symptomatic dengue infection.
Conclusion: Household investigation demonstrated a high proportion of household members positive for dengue infection,
including a number of inapparent cases, the frequency of which was higher in SEA than in LA.
Citation: Dussart P, Baril L, Petit L, Beniguel L, Quang LC, et al. (2012) Clinical and Virological Study of Dengue Cases and the Members of Their Households: The
Multinational DENFRAME Project. PLoS Negl Trop Dis 6(1): e1482. doi:10.1371/journal.pntd.0001482
Editor: Eva Harris, University of California, Berkeley, United States of America
Received January 5, 2011; Accepted November 30, 2011; Published January 24, 2012
Copyright:  2012 Dussart et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The DENFRAME project (www.denframe.org) is supported by a grant from the European Commission (6th Framework Programme: 2005-INCO-DEV2
no; 517711), by the International Division of the Institut Pasteur (Paris, France) and the Institut Pasteur International Network. Platelia
TM Dengue NS1 Ag tests were
provided by Bio-Rad Laboratories, Marnes La Coquette, France. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pdussart@pasteur-cayenne.fr
Introduction
Dengue is the most important mosquito-borne viral disease of
humans. The disease is now endemic in more than 100 countries
and threatens more than 2.5 billion people. It currently affects
about 50 to 100 million people each year [1]. Dengue viruses
(DENV) are enveloped, single-stranded positive-sense RNA viruses
(family Flaviviridae, genus Flavivirus). There are four types of DENV:
DENV-1, DENV-2, DENV-3 and DENV-4. Dengue virus
infection induces life-long protective immunity to the homologous
serotype, but confers only partial and transient protection against
subsequent infections with any of the other three serotypes [2]. The
disease spectrum ranges from inapparent infection or mild dengue
fever [3], probably the most common form, to a potentially severe
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known as severe dengue. Uncommonly, severe dengue may
manifest as hepatitis, encephalopathy or rhabdomyolysis [2,4–7].
About 500,000 people are estimated to have severe dengue and
about 25,000, mostly children, die from it each year [8]. The
underlying causes determining the outcome of DENV infection
remain unknown. Although previous exposure, viral strain and
human host genetic polymorphisms also influence the clinical
outcome of DENV infection, we still know little about the complex
interplay between host and pathogen in the pathogenesis of dengue
[9–12].
Inapparent infections have largely been detected retrospectively
through serology. The uses of genome detection or virus isolation
have enabled detection of inapparent infections in cluster studies
designed to detect natural infections in the community [13,14].
The present study was designed to identify symptomatic and
inapparent dengue-infected subjects in genetically-related individ-
uals living in the same household, in line with the main aim of the
DENFRAME project which is to explore the influence of human
genetic variants and their functional roles in the pathogenesis of
dengue disease in humans. We based the identification of dengue-
infected subjects upon virological techniques, namely virus
isolation and detection of the genome. We also took this
opportunity to evaluate prospectively a commercial NS1 capture
assay [15,16] that could potentially be implemented in laboratories
for the diagnosis of acute dengue [17–19].
Methods
Objectives
A multinational, prospective study was conducted in South-East
Asia (Cambodia and Vietnam) and Latin America (Brazil and
French Guiana). We used virological techniques to identify dengue
patients diagnosed at the acute phase of disease among the patients
presenting with dengue-like illness. We then performed a household
investigation, comparing clinical data and biological markers from
subjects with a broad range of dengue disease patterns, including
inapparent dengue cases that are rarely captured in clinical studies.
This clinical study’s aims were: (i) to estimate the proportion of
inapparent dengue infections among members of the households of
laboratory-confirmedsymptomatic denguecases, (ii)to calculate the
proportion of dengue-infected subjects at the time of the household
investigation, and (iii) to compare clinical and biological data from
inapparent and symptomatic dengue-infected subjects.
Study sites
Five institutions were involved in this study during the
recruitment period: Instituto Evandro Chagas (IEC) in Bele ´m (Para ´
state, Brazil), Institut Pasteur du Cambodge (IPC) in Phnom Penh
(Cambodia), Institut Pasteur de la Guyane (IPG) in Cayenne (French
Guiana) and Institut Pasteur de Ho Chi MinhVille (IPHCM) in Vietnam
were responsible for the recruitment of patients and virological
analyses; the Institut Pasteur (IP) in Paris (France) designed the study
and was responsible for central monitoring and data analysis.
As shown in the two maps (Figure 1), volunteers were recruited
at four clinical sites: Vinh Thuan District Hospital (Vietnam),
Kampong Cham Referral Hospital (Cambodia), the IPG in
Cayenne (French Guiana) and public outpatient and emergency
rooms managed by the Bele ´m Health Secretariat in the districts of
Guama ´, Marco, Marambaia and Sacramenta, and the outpatient
unit of the IEC (Brazil). The virology laboratories of the four
institutions responsible for recruitment are all National Reference
Centers (NRC) for Arboviruses (IEC is also a WHO collaborative
center). These laboratories carried out virological, NS1 antigen
(Platelia Dengue NS1 Antigen, Bio-Rad, Marnes La Coquette,
France), and serological techniques.
Study design
We recruited subjects with acute dengue-like illness at the study
sites. These subjects were identified by the treating physicians and
were included if they satisfied the following criteria: (i) aged over
24 months; (ii) oral temperature .38uC and onset of symptoms
within the last 72 h; and (iii) presenting with at least one clinical
manifestation suggestive of dengue-like illness: severe headache,
retro-orbital pain, myalgia, joint pain, rash or any bleeding
symptom. Furthermore, for inclusion in the second step of the
study, the subject had to come from a familial household
containing more than two people during the seven days preceding
illness. We first identified the dengue-infected subjects (referred to
in this study as Dengue Index Cases or DIC) and non-dengue-
infected subjects (defined as Non-Dengue Cases - NDC) on the
basis of virological results from an acute sample (see below). We
then recruited individuals from the households of the DIC. We
thus constituted three groups of participants: 1) DIC, 2) household
members (HHM), and 3) NDC not related to the DIC. For all
groups (DIC, HHM and NDC), we applied the same exclusion
criteria: women who were pregnant or breastfeeding, individuals
with a focal source of infection (e.g. otitis media, pneumonia,
meningitis), patients presenting with a known chronic illness, and
patients with malaria. Moreover, to ensure the feasibility of this
study, each study site was asked to target a convenient sample of
50 households and to recruit subjects from July 2006 to June 2007
in line with the approval granted by the Institutional Review
Board and the timing of the dengue season at each site.
Clinical data and blood sample collection
Participants were examined during sequential visits, as shown in
the study design charts (Figure 2). At each visit, data were collected
with a standardized questionnaire. Severe dengue cases were
classified, according to WHO recommendations on the basis of the
clinical data. Biological data were also recorded at the sequential
visits [2]. Blood samples were collected during the visits and were
Author Summary
Dengue is the most important mosquito-borne viral
disease in humans. This disease is now endemic in more
than 100 countries and threatens more than 2.5 billion
people living in tropical countries. It currently affects about
50 to 100 million people each year. It causes a wide range
of symptoms, from an inapparent to mild dengue fever, to
severe forms, including dengue hemorrhagic fever. Cur-
rently no specific vaccine or antiviral drugs are available.
We carried out a prospective clinical study in South-East
Asia and Latin America, of virologically confirmed dengue-
infected patients attending the hospital, and members of
their households. Among 215 febrile dengue subjects, 177
agreed to household investigation. Based on our data, we
estimated the proportion of dengue-infected household
members to be about 45%. At the time of the home visit,
almost three quarters of (29/39) presented an inapparent
dengue infection. The proportion of inapparent dengue
infection was higher in South-East Asia than in Latin
America. These findings confirm the complexity of dengue
disease in humans and the need to strengthen multidis-
ciplinary research efforts to improve our understanding of
virus transmission and host responses to dengue virus in
various human populations.
Dengue Clinical Study in Asia and Latin America
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for dengue diagnosis and biological testing. Blood sample volume
was adapted for children weighing less than 20 kg.
Paired blood samples were collected for subjects presenting
dengue-like illness to allow classification as DIC or NDC: during
the acute phase (Visit 1) and during the convalescence phase (Visit
4: 15 to 21 days after the onset of fever). Blood samples were taken
from hospitalized DIC within 24 hours of defervescence (Visit 3).
HHM were visited at home for blood collection within 24 to
72 hours of DIC identification (Home Visit 1). For practical and
logistical reasons this delay of up to 72 hours was unavoidable.
HHM were supplied with a monitoring diary card and a
thermometer, to enable them to follow their temperature over a
7-day period. For HHM with a positive diagnosis of dengue or
with an onset of fever during the seven days of monitoring, a
second visit with blood collection for dengue diagnosis was
organized (Home Visit 2). Blood analyses included virological and
serological dengue diagnosis, complete blood count, transaminases
and bilirubin levels. Finally, the data were coded and entered into
the computer via a secure website specifically developed with the
PHP/MySQL system.
Classification of dengue cases on the basis of acute
dengue diagnosis
All serum samples collected at Visit 1 or at Home Visit 1 or
Home Visit 2 were tested: (i) for acute dengue diagnosis, defined as
positive virus isolation on mosquito cells [20] and/or positive viral
RNA detection by reverse transcriptase-polymerase chain reaction
(RT-PCR) [21], and (ii) for the diagnosis of early convalescent
dengue cases based on a standardized DENV IgM capture
enzyme-linked immunosorbent assay (MAC-ELISA) [22], and
DENV IgG detection by indirect ELISA (in-house protocol
developed by each NRC for Arboviruses). NS1 antigen detection
was also performed.
Only subjects with febrile dengue infection diagnosis were
classified as DIC. Subjects in the early stage of dengue
convalescence at Visit 1 (i.e. positive NS1 antigen detection with
concomitant DENV IgM detection, or isolated DENV IgM
detection with no positive viral tests) were not classified as DIC;
we did not perform a household investigation for them. For the
classification of dengue-infected HHM at Home Visit 1, we
included both HHM with an acute (febrile or inapparent) dengue
infection diagnosis and HHM with isolated DENV IgM detection,
presumably related to an infection preceding that of the DIC (i.e in
the early convalescence phase). During the 7-day period of home
monitoring, severalnew febrile cases of dengue-infected HHMwere
also confirmed through Home Visit 2.
We were unable to use the DENV IgM/IgG ratio to distinguish
between primary and secondary dengue infections, due to a lack of
standardization of DENV IgG tests among laboratories [23]. We
therefore established two groups of dengue-infected participants,
based on the presence or absence of DENV IgG during the acute
phase of the disease. In this study, we considered the presence of
DENV IgG in the acute phase of the study to be suggestive of
previous dengue infection. All sera were also checked for DENV
IgM and IgG at Visit 4. Finally, if all these dengue tests were
negative, participants were classified as NDC.
Ethics
The study was approved by the Institutional Review Board of
the Institut Pasteur and by the ethics committees of each of the
countries concerned. It was conducted in accordance with the
Declaration of Helsinki, and the participants or the parents of
minors participating in the study gave written informed consent
Figure 1. Localization of the four clinical sites. A: in South-East Asia (Cambodia and Vietnam). B in Latin America (Brazil and French Guiana).
doi:10.1371/journal.pntd.0001482.g001
Dengue Clinical Study in Asia and Latin America
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B: Step 2, Identification of household members (HHM).
doi:10.1371/journal.pntd.0001482.g002
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standard operating procedures and informed consent forms were
adapted and translated for each clinical site. All the documenta-
tion was accessible through a dedicated website with a specific
login access (www.denframe.org). The centralized electronic
database was based at the Institut Pasteur in Paris and registered
with the Commission Nationale de l’Informatique et des Liberte ´s (CNIL) in
France.
Statistical methods
We present here the data from all four study sites in Latin
America and South-East Asia. DIC are described according to
region, disease severity, DENV type, age group and IgG status.
We estimated the proportion of inapparent dengue infections
among HHM, and we calculated the proportions of dengue-
infected subjects among household subjects, in total and according
to the IgG status at the time of household investigation. We
compared clinical data and biological markers between inapparent
dengue-infected subjects, symptomatic dengue-infected subjects,
and non-dengue-infected participants at the time of the household
investigation. We created binary variables to evaluate the potential
effect of DENV infection on biological markers (hematocrit,
platelets, neutrophils, lymphocytes, monocytes, ASAT, ALAT,
bilirubin). For lymphocytes and neutrophils, we used a threshold of
2610
9/l. We used chi-squared or Fisher’s exact tests to compare
categorical variables between symptomatic cases, inapparent
dengue-infected cases and non-dengue-infected subjects among
HHM. Univariate and multivariable logistic regression models
were used to assess the effect of covariates on the odds ratios (OR)
of symptomatic dengue-infected cases, inapparent dengue-infected
cases, and non-dengue-infected subjects among HHM. For the
multivariable logistic regression models including data from
household members, we used two-stage hierarchical regression
models taking into account the family household structure [24].
Potential confounders with a P value of less than 0.20 in univariate
analysis were retained for the final multivariable analyses. STATA
version 10.0 (Stata Corp., College Station, TX, USA) and a
significance level of 5% were used for all statistical analyses.
Results
Flowcharts for the recruitment of participants at each step are
shown in Figure 3.
Step 1: identification of dengue index cases (DIC)
We screened 473 febrile subjects for dengue infection. Thirty
(6.3%) had at least one criterion for non inclusion in the study at
presentation; the remaining 443 (93.7%) were included in the
study. We identified 215 (48.5%) of these 443 subjects as DIC, 21
(4.7%) as dengue convalescent cases, 187 (42.2%) as NDC, and 20
(4.5%) could not be classified because some biological markers
were lacking. Recruitment levels during the study period were very
low in French Guiana (9 DIC and 24 NDC), whereas there had
been a large number of dengue cases during the rainy season of the
previous year [25]. For the 215 subjects classified as DIC, 149
(69.3%) were positive by genome detection and viral isolation, 43
(20.0%) were positive by genome detection only, 15 (7.0%) were
positive by viral isolation only, and a very few subjects (n=8,
3.7%) were ultimately classified as DIC by the virologists, based on
positive NS1 detection, clinical data and serological results
(negative IgM at Visit 1 followed by seroconversion IgM at
convalescent phase).
The proportions of subjects classified as either NDC or DIC
differed between Latin America and South-East Asia: 69.5% (130/
187) of the total NDC in the study, and 47.0% (101/215) of the
DIC, were recruited in Latin America whereas 30.5% (57/187) of
the NDC and 53.0% (114/215) of the DIC were recruited in
South-East Asia (P,10
24) (Figure 3A). In other words, in Latin
America, in two thirds of subjects presenting with dengue-like
illness, the cause was not related to dengue infection. Given the
inclusion criteria, the dengue-like illness symptoms were not
different between NDC and DIC (data not shown). However, all
biological variables, including counts of platelets, lymphocytes and
neutrophils, were significantly lower, whereas hematocrit and liver
enzyme levels were higher in the DIC group than in the NDC
group (data not shown).
Table 1 shows the distribution of DIC by region and according
to IgG status at Visit 1 as a function of DENV type and age group.
The proportions of severe dengue and dengue fever cases with
DENV IgG (suggestive of previous DENV infection) and without
DENV IgG in the acute phase were similar (Table 1): 15 (55.6%)
severe dengue cases tested negative for DENV IgG and 12 (44.4%)
tested positive for DENV IgG, versus 49 (31.8%) and 105 (68.2%)
of the subjects with non severe disease, respectively (P=0.017).
DENV-1, -2 and -3 were found with similar frequencies in South-
East Asia, whereas DENV-3 predominated in Latin America.
Fifteen of the severe dengue cases reported in South-East Asia
were infected with DENV-2 (53.6%; 15/28). Interestingly, seven
severe dengue cases positive for DENV-2 virus and negative for
DENV IgG in the acute phase but with subsequent DENV IgM
and IgG seroconversion were identified. This serological pattern
suggests that these patients had primary DENV infection. Two
DIC in Vietnam were reported with co-detection of multiple
DENV strains by RT-PCR: DENV-2/DENV-1 and DENV-4/
DENV-2 respectively; the viral cultures were negative for both
subjects. Only the first virus detected was considered for further
statistical analysis (DENV-2 and DENV-4, respectively).
According to the WHO criteria, twenty-eight (13.0%) subjects
were classified as severe dengue (based on severe plasma leakage
and/or severe hemorrhages and/or severe organ impairment). All
these cases were from clinical sites in South-East Asia (25 in
Vietnam and 3 in Cambodia, as presented in Table S1). At visit 1,
presentation with the following combination of features was
significantly associated with the occurrence of severe dengue in
this population: being male, over the age of seven years, with no
retro-orbital pain but with bleeding, low monocyte count, normal
liver enzyme levels and DENV-2 type infection.
For 163 (75.8%) DIC, data were available for all the biological
markers at visits 1 and 4 (Figure 3A). All these markers had
returned to normal levels by visit 4, and all participants, including
the 28 severe dengue cases displayed clinical recovery from dengue
disease (data not shown).
Step 2: identification of household members (HHM)
Agreement for household investigations was obtained from 177
(82.3%) DIC, corresponding to a total of 651 household members.
We compared the distribution of the covariates (as listed in Table
S1) between the 38 DIC with no familial investigation and the 177
DIC who underwent familial investigation; no significant differ-
ences were found in the distribution of the covariates between
these two groups (data not shown). All 28 patients with severe
dengue infection underwent household investigation. In total, 141
(21.7%) of the 651 household members refused to participate in
the study. We therefore screened 510 participants, 497 (97.5%) of
whom were eligible for the study. All but one of these 497
household members were genetically related to the DIC. Eighty-
four were not classifiable due to the lack of some biological results.
Full assessment of DENV infection was carried out according to
Dengue Clinical Study in Asia and Latin America
www.plosntds.org 5 January 2012 | Volume 6 | Issue 1 | e1482Figure 3. Identification of the dengue index cases (DIC) and of the household members (HHM). A: Identification of DIC in Step 1. B:
Recruitment of HHM for 177 DIC during Step 2. * Full assessment of DENV infection was performed for a total of 413 HHM at Home Visit 1, and 312
subjects were considered as non-dengue-infected at that time. Five of them developed a dengue fever and were excluded from our analysis, defining
a total of 408 HHM at Home Visit 1. Among them, 307 (312 - 5) subjects may have had an inapparent dengue infection after Home Visit 1 as we did
not perform blood sample collection at Home Visit 2 for non-symptomatic subjects.
doi:10.1371/journal.pntd.0001482.g003
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(Figure 3B) during Home Visit 1.
At the time of the household investigation (Home Visit 1), 39
subjects were identified as being in the acute phase of dengue
infection: 29 (74.4%) cases were inapparent and 10 (25.6%)
had symptomatic dengue infection. An additional 62 subjects
were classified as being in the early phase of convalescence from
dengue infection. The remaining 312 subjects were considered as
non-dengue-infected at the time of Home Visit 1 (Figure 3B);
however, five of them developed some clinical symptoms of dengue
fever and were laboratory-confirmed as having acute dengue
infection during the 7-day home monitoring. We excluded them
(n=5) from the remaining analysis (n=312 subjects with 7-day
home monitoring) that thus included 307 subjects (Figure 3B). It
should be noted that a second home visit and blood sampling was
notpossible, forethical and logistical reasons,forHHMwithoutany
Table 1. Characteristics of dengue index cases (DIC, n=215).
Acute serum samples (n=215)
Latin America (n=101) South-East Asia (n=114)*
Negative IgG (n=14) Positive IgG (n=87) Negative IgG (n=60) Positive IgG (n=51)
Severe
dengue
n=0(%)
Dengue
fever
n=6(%)
Non
classifiable
n=8(%)
Severe
dengue
n=0(%)
Dengue
fever
n=70 (%)
Non
classifiable
n=17 (%)
Severe
dengue
n=15 (%)
Dengue
fever
n=43 (%)
Non
classifiable
n=2(%)
Severe
dengue
n=12 (%)
Dengue
fever
n=35 (%)
Non
classifiable
n=4(%)
Dengue
type
DENV-1 - 3 (50.0) - - 8 (11.4) 3 (17.6) 4 (26.7) 20 (46.5) - 2 (16.7) 14 (40.0) -
DENV-2 - - 8 (100.0) - 13 (18.7) 1 (5.9) 7 (46.7) 12 (27.9) - 7 (58.3) 6 (17.2) -
DENV-3 - 3 (50.0) - - 47 (67.1) 13 (76.5) 3 (20.0) 9 (21.0) 1 (50.0) 1 (8.3) 11 (31.4) 2 (50.0)
DENV-4 - - - - - - - 1 (2.3) - - 2 (5.7) 1 (25.0)
Missing
data
- - - - 2 (2.8) - 1 (6.6) 1 (2.3) 1 (50.0) 2 (16.7) 2 (5.7) 1 (25.0)
Age-
group
(years)
[2–7] - - - - 3 (4.3) 2 (11.8) 2 (13.3) 21 (48.9) 2 (100.0) 2 (16.7) 13 (37.1) -
[7–10] - 1 (16.7) 1 (12.5) - - 1 (5.9) 3 (20.0) 9 (20.9) - 4 (33.3) 6 (17.1) 1 (25.0)
.10 - 5 (83.3) 7 (87.5) - 67 (95.7) 13 (76.4) 10 (66.7) 13 (30.2) - 6 (50.0) 16 (45.7) 3 (75.0)
Missing
data
--- -- 1 ( 5 . 9 ) - - - - - -
*For 3 subjects infected by DENV-2, data related to IgG status were missing: 2 dengue fever cases and 1 severe dengue case.
Distribution of DIC is provided by region in relation to the presence of WHO criteria for severe dengue and IgG status during the acute phase.
doi:10.1371/journal.pntd.0001482.t001
Table 2. Distribution of the participants in the clinical study (n=590).
Brazil French Guiana Cambodia Vietnam Total
n=134 (%) n=28 (%) n=180 (%) n=248 (%) n=590 (%)
[IgG+/IgG2] [IgG+/IgG2] [IgG+/IgG2] [IgG+/IgG2] [IgG+/IgG2]
Non DENV-infected subjects 47 (15.4) 9 (3.0) 98 (32.1) 151 (49.5) 305 (51.7)
[44/3] [3/6] [95/3] [97/54] [239/66]
Missing IgG data 1 - - 1 2 (0.3)
Early convalescent phase or
convalescent phase (HHM only)
4 (6.5) 3 (4.9) 22 (36.1) 32 (52.5) 61 (10.3)
[4/0] [2/1] [22/0] [25/7] [53/8]
Missing IgG data - - - 1 1 (0.2)
DENV-infected at the acute phase (DIC+HHM) 82 (37.6) 16 (7.4) 60 (27.5) 60 (27.5) 218 (37.0)
Symptomatic [69/6] [3/10] [30/19] [16/36] [118/71]
Missing IgG data - - - 3 3 (0.5)
Inapparent dengue infection [6/1] [1/2] [8/3] [3/5] [18/11]
All participants were identified at Visit 1 for Dengue Index Cases (DIC) and at Home Visit 1 for dengue-infected household members (HHM). Their distribution is
presented by country, according to DENV-infected status and IgG status.
doi:10.1371/journal.pntd.0001482.t002
Dengue Clinical Study in Asia and Latin America
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Household members.
Non-dengue-
infected
n=307 (%)
Inapparent
dengue infection
n=29 (%) Crude OR 95% CI P* Adjusted OR 95% CI P
Sex
Male 135 (44.0) 16 (55.2) 1
Female 172 (56.0) 13 (44.8) 0.64 [0.3–1.4] 0.25
Age (years)
[2–7] 16 (5.2) 5 (17.2) 1 1
[7–10] 17 (5.5) 2 (6.9) 0.38 [0.1–2.2] 0.28 0.79 [0.1–6.5] 0.83
.10 274 (89.3) 22 (75.9) 0.26 [0.1–0.7] 0.015 0.41 [0.1–1.8] 0.25
Weight-based Z-score
[21, 1] 89 (29.0) 6 (20.7) 1
,21 195 (63.5) 21 (72.4) 1.6 [0.6–4.1] 0.33
.1 23 (7.5) 2 (6.9) 1.3 [0.2–6.8] 0.76
Hematocrit (%)
#36 93 (30.3) 7 (24.1) 1
.36 212 (69.1) 22 (75.9) 1.38 [0.6–3.3] 0.48
Missing data 2 (0.6) -
Platelets (610
9/L)
.100 296 (96.4) 26 (89.7) 1 1
#100 10 (3.3) 3 (10.3) 3.42 [0.9–13.2] 0.075 1.71 [0.2–12.3] 0.6
Missing data 1 (0.3) -
Neutrophils (610
9/L)
.2 288 (93.8) 18 (62.1) 1 1
#2 18 (5.9) 11 (37.9) 9.8 [4–23.8] ,0.0001 7.75 [2.5–24] ,0.0001
Missing data 1 (0.3) -
Lymphocytes (610
9/L)
.2 243 (79.2) 15 (51.7) 1 1
#2 63 (20.5) 14 (48.3) 3.6 [1.6–7.8] 0.001 2.08 [0.7–5.6] 0.15
Missing data 1 (0.3) -
Monocytes (610
9/L)
.0.2 298 (97.1) 23 (79.3) 1 1
#0.2 8 (2.6) 6 (20.7) 9.72 [3.1–30] ,0.0001 9.1 [1.8–44] 0.006
Missing data 1 (0.3) -
ASAT
a (UI/L)
#30 225 (73.3) 17 (58.6) 1 1
.30 81 (26.4) 11 (37.9) 1.8 [0.8–4] 0.15 1.96 [0.7–5.2] 0.17
Missing data 1 (0.3) 1 (3.5)
ALAT
b (UI/L)
#35 261 (85.0) 22 (75.9) 1
.35 45 (14.7) 6 (20.7) 1.58 [0.6–4.1] 0.35
Missing data 1 (0.3) 1 (3.4)
Bilirubin (mmol/L)
#17 262 (85.3) 24 (82.8) 1
.17 42 (13.7) 3 (10.3) 0.78 [0.2–2.7] 0.69
Missing data 3 (1.0) 2 (6.9)
IgG at Visit 1
Negative 66 (21.5) 11 (37.9) 1 1
Positive 239 (77.8) 18 (62.1) 0.45 [0.2–1.0] 0.051 0.37 [0.1–1.04] 0.06
Missing data 2 (0.7) -
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the 307 remaining subjects, some may have had an inapparent
dengue infection after Home Visit 1. Therefore, we considered that
at least 101 (39 acute or 62 early convalescent) dengue infections
were found amongst 408 HHM (24.8%; 95% confidence interval
(CI): 20.6–28.9) at the time of Home Visit 1 (Figure 3B). Thus,
adding together the 177 DIC and the 101 DENV-infected HHM,
the overall proportion for dengue among the study participants was
estimated at 47.5% (278/585; 95% CI: 43.5–51.6) (Figure 3B). We
have also estimated these proportions according to the IgG status
(Table 2) at the time of Home Visit 1 (excluding the 5 subjects with
known symptomatic infection – 3 were IgG positive and 2 were IgG
negative). Among the 585 subjects, 6 had missing IgG data. Among
425 subjects with positive IgG, the estimated proportion of dengue-
infected subjects was 43.8% (186/425; 95% CI: 39.0–48.5) and,
among the 154 with negative IgG, this estimated proportion was
57.1% (88/154; 95% CI: 49.3–65.0).
In 101 (57.1%) households, there was only one dengue-infected
case. For the 76 (42.9%) households with at least two dengue-
infected cases, DENV type had been determined for all subjects in
29 households. Nine (31.0%) households were found to have two
different DENV types circulating during the same time period:
DENV-1 & DENV-3 (n=2 in Brazil, n=4 in Cambodia), DENV-
1 & DENV-2 (n=1 in Vietnam), and DENV-2 & DENV-3 (n=2
in Vietnam).
Hematologic and hepatic biological markers observed among
non-dengue-infected cases (n=307), inapparent dengue-infected
cases (n=29), and symptomatic dengue-infected subjects (n=192)
are described in Table S2. Tables 3 & 4 show comparisons
between non-dengue-infected and inapparent dengue-infected
cases, and symptomatic and inapparent dengue-infected subjects,
respectively, among the household subjects. Table S3 presents the
main characteristics of subjects with acute dengue infection
compared to non-dengue-infected subjects among the household
subjects. In the comparisons between non-dengue-infected and
inapparent dengue-infected subjects, taking into account potential
confounders, only neutrophil and monocyte levels differed
significantly whereas presence of IgG at Visit 1 was almost
significant with the non-dengue-infected group. The comparison
between symptomatic and inapparent dengue-infected subjects
(Table 4) showed significant difference between groups for
lymphocyte counts and positive NS1 antigen detection. In this
analysis, no significant difference was found for DENV types
identified or IgG detection during the acute phase.
Discussion
Several previous epidemiological studies have focused on
school-based surveillance aiming at improving dengue-vector
control measures [3,14], studying the dynamics of patterns of
dengue transmission [26–28] or describing a model that takes into
account the role of human movement in the transmission
dynamics of vector-borne pathogens [29]. Earlier cluster investi-
gation methods were designed as an alternative approach to the
commonly used prospective cohort study method for investigating
the natural history of dengue virus infection in South-East Asia
and Latin America [13,30]. Although different study designs have
demonstrated the feasibility of identification of inapparent dengue
cases, it remains difficult to recruit these subjects. We designed our
study to include family household investigation in order to identify
a group of inapparent dengue-infected subjects and to compare
them with symptomatic dengue-infected and non-dengue-infected
subjects living in the same family household. The study design was
based on family household recruitment specifically in order to
collect data and biological samples, and to study secondarily the
host susceptibility to dengue infection and disease. Unlike studies
based on cohorts from hospital referrals, this multi-country study
captured dengue cases ranging from inapparent infections,
through mild disease to severe dengue fever, using definitions of
clinical cases and diagnostic methodology standardized across the
four sites. The period of inclusion, from July 2006 to June 2007,
spanned the dengue season at each site, although incidence of
dengue was low that year in French Guiana.
The main objective of this study was to identify dengue
infections and particularly inapparent infections among dengue
patients’ household family members in South-East Asia and Latin
America. Based on our data, we estimated the proportion to be
about 45% among those participating in the household study.
Most of the dengue cases studied had symptomatic infections,
covering the spectrum of disease from dengue fever to severe
dengue cases. We also identified inapparent infections in the
population. We observed dengue-infected subjects classified as
DIC and some of their HHM without acute dengue infection but
with a positive IgM detection, suggesting an early convalescent
phase after dengue infection with no clinical symptoms. In this
study we identified 29 inapparent dengue infections but we believe
this number underestimates the proportion of inapparent dengue
cases because we were not able to take blood samples from non-
symptomatic subjects at Home Visit 2.
We postulated that dengue is transmitted to members of the
DIC’s family household during the period of the index subject’s
infection, and thus designed our study to detect inapparent dengue
infections with a home visit organized shortly after identification
of DIC. Obviously, we cannot confirm whether the index subject’s
DIC was always the source of infection in other family members,
but we can postulate that a non-hospitalized DIC who remains
at home during acute illness represents a potential source of
DENV transmission to Aedes. According to our study design,
clustering of cases within a household could be the result of a single
or very few infected mosquitoes biting different household
members during a short period of time, perhaps within a single
gonotrophic cycle as previously suggested [14,31]. This is also
consistent with a previous observation that over periods from 1 to
3 days, dengue cases were clustered within short distances, i.e.,
within a household [32]. No mosquito captures were, however,
conducted in our study to identify DENV-positive Aedes mosqui-
toes. DENV sequencing would help resolve the extent of localized
transmission.
*Potential confounders with a P value of less than 0.20 in univariate analysis were retained for the final multivariable analyses. In this table: age, platelets, neutrophils,
lymphocytes, ASAT and IgG at Visit 1.
aASAT: Aspartate amino transferase.
bALAT: Alanine amino transferase.
Univariate and multivariable logistic regression were used for analyses.
doi:10.1371/journal.pntd.0001482.t003
Table 3. Cont.
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Symptomatic
dengue-infected
n=192 (%)
Inapparent
dengue
infection
n=29 (%) Crude OR 95% CI P* Adjusted OR 95% CI P
Sex
Male 103 (53.6) 16 (55.2) 1
Female 89 (46.4) 13 (44.8) 0.94 [0.4–2.1] 0.88
Age (years)
[2–7] 38 (19.8) 5 (17.2) 1
[7–10] 27 (14.1) 2 (6.9) 0.56 [0.1–3.1] 0.51
.10 127 (66.1) 22 (75.9) 1.32 [0.5–3.7] 0.6
Weight-based Z-score
[21, 1] 75 (39.1) 6 (20.7) 1 1
,21 102 (53.1) 21 (72.4) 2.57 [0.9–6.7] 0.052 2.54 [0.6–10.4] 0.20
.1 15 (7.8) 2 (6.9) 1.66 [0.3–9.1] 0.55 4.11 [0.4–43] 0.24
Hematocrit (%)
#36 38 (19.8) 7 (24.1) 1
.36 154 (80.2) 22 (75.9) 0.77 [0.3–1.9] 0.59
Platelets (610
9/L)
.100 126 (65.6) 26 (89.7) 1 1
#100 66 (34.4) 3 (10.3) 0.22 [0.1–0.7] 0.016 0.23 [0.4–1.4] 0.11
Neutrophils (610
9/L)
.2 76 (39.6) 18 (62.1) 1 1
#2 116 (60.4) 11 (37.9) 0.4 [0.2–0.9] 0.026 0.5 [0.15–1.6] 0.25
Lymphocytes (610
9/L)
.2 16 (8.3) 15 (51.7) 1 1
#2 176 (91.7) 14 (48.3) 0.08 [0.03–0.2] ,0.0001 0.09 [0.02–0.4] 0.001
Monocytes (610
9/L)
.0.2 114 (59.4) 23 (79.3) 1 1
#0.2 78 (40.6) 6 (20.7) 0.38 [0.1–0.9] 0.045 0.65 [0.16–2.7] 0.56
ASAT
a (UI/L)
#30 75 (39.1) 17 (58.6) 1 1
.30 117 (60.9) 11 (37.9) 0.4 [0.2–0.9] 0.034 0.4 [0.1–1.5] 0.17
Missing data - 1 (3.5)
ALAT
b (UI/L)
#35 112 (58.3) 22 (75.9) 1 1
.35 80 (41.7) 6 (20.7) 0.38 [0.15–0.9] 0.046 0.52 [0.14–1.9] 0.33
Missing data - 1 (3.4)
Bilirubin (mmol/L)
#17 175 (91.1) 24 (82.8) 1
.17 14 (7.3) 3 (10.3) 1.56 [0.4–5.8] 0.51
Missing data 3 (1.6) 2 (6.9)
DENV type
DENV-1 50 (26.0) 5 (17.2) 1
DENV-2 50 (26.0) 7 (24.2) 1.4 [0.4–4.7] 0.59
DENV-3 79 (41.2) 13 (44.8) 1.64 [0.5–4.9] 0.37
DENV-4 3 (1.6) -
Missing data 10 (5.2) 4 (13.8)
IgG at Visit 1
Negative 71 (37.0) 11 (37.9) 1
Positive 118 (61.4) 18 (62.1) 0.98 [0.4–2.2] 0.97
Missing data 3 (1.6) -
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virus isolation and detection of the genome. We also used NS1
antigen detection, a more recently recognised diagnostic tool. As
for many tropical infectious diseases, there is an urgent need for
validated diagnostic tools for dengue. In parallel with the
virological techniques, we evaluated detection of the NS1 antigen
with the Platelia Dengue NS1 Ag test. In this study, this test was
found to have good sensitivity (83.6%; 95% CI: 78.5–88.6) and
specificity (98.9%; 95% CI: 96.6–99.9) in both Asia and Latin
America, as reported in previous studies [17,33,34]. A recent
multi-country study observed unequal sensitivity between geo-
graphical regions that remains unexplained, suggesting further
assessments are needed [35]. The use of viral detection antigen is
particularly useful during the first five days of illness with NS1
assays that are significantly more sensitive for primary than
secondary dengue [18,34,36]. However, NS1 antigen could be
detected in only 20% of inapparent DENV-infection. This finding
suggests that NS1 antigen may have a role in dengue disease
pathogenesis and also indicates that this test cannot be relied upon
for detection of inapparent dengue infection.
By comparing HHM not infected with dengue with those
presenting with inapparent dengue infection, we showed that
neutrophil and monocyte counts were early indirect biological
markers of dengue infection, whereas platelet counts and the
frequency of IgG detection at the first visit did not differ between
the two groups (Table 3). A comparison of inapparent dengue-
infected HHM with symptomatic dengue-infected subjects showed
that lymphocyte counts and detection of the NS1 antigen differed
significantly between these two groups (Table 4). Moreover, the
NS1 antigen was detected during the acute phase in most of the
dengue cases tested, and the sensitivity of this test was even higher
in severe dengue cases (26/28, Table S1), possibly reflecting higher
viral loads. These findings may indirectly reflect the progression of
the immune response to DENV, leading in some cases to severe
acute lymphopenia and a lack of virological control, with high
rates of NS1 antigen circulation in the blood that may be
correlated with high-level or prolonged viremia [7,36]. Severe
dengue cases were also more likely to be male, to have lower
monocyte counts or normal liver enzyme levels, and to be infected
with DENV-2, although quantitative RT-PCR did no permit
study of the magnitude of the viremia. We showed that half of the
severe dengue cases had not previously been infected with DENV,
as confirmed by the occurrence of DENV IgG seroconversion
during convalescent phase [7]. In all dengue-infected subjects,
including inapparent, we observed a decrease in neutrophil and
monocyte counts. On one hand, it may suggest a direct effect of
dengue illness on hematopoiesis, although such an effect is in
conflict with data reported elsewhere in the literature [37]. On the
other hand, DENV is detected in peripheral monocytes during
acute disease, and the infection of monocytes leads to cytokine
production, suggesting that virus-monocyte interactions are
relevant to pathogenesis [38–40]. Moreover, DENV can induce
apoptosis in monocytes, and this may lead to decreases in the
number of these cells in severe dengue cases [41].
In this study we only observed severe dengue cases in South-
East Asia. Disease severity and pathogenesis remain largely
unexplained and certainly related to complex interactions of
several factors, including virus strain, immune response to previous
dengue infection and host genetic background. The introduction
of the Asian 1 DENV-2 genotype into the Americas in the 1980s
led to the emergence of severe dengue cases on this continent.
Following this introduction a new genotype emerged, named
Asian/American DENV-2 genotype [42–44]. During the study
period, this Asian/American genotype was circulating in French
Guiana (Philippe Dussart, personal data) and probably in the
north of Brazil, however DENV-2 did not cause an outbreak and
we did not report any severe dengue case among Brazilian
subjects.
Two constraints of the study design deserve mention. All
methods (biological markers, virological testing, NS1 antigen
detection and IgM serology) were standardized across the four
reference laboratories, with the exception of the IgG ELISA. As a
consequence, we were unable to calculate the IgM/IgG ratio
[45,46]. However, as the intention was to include dengue cases
during the acute phase of infection, this ratio was not a crucial
endpoint for the study. Another constraint of this study was that
we did not include infants and children below 24 months of age in
the DENFRAME project. However, several previous reports
already provide insight into the epidemiology of dengue in this
specific population [47–50].
These findings confirm the complexity of dengue disease in
humans and the need to strengthen multidisciplinary research
efforts to improve our understanding not only of virus transmission
but also host responses to DENV in various human populations. It
will therefore be interesting, based on clinical data and biological
samples collected in this study, to further evaluate the host
susceptibility to dengue infection and disease using family-based
association analyses. Moreover, we think that technological transfer
of standardized diagnostic methods in laboratories based in tropical
countries is essential if we are to estimate disease burden and to
optimize vector control interventions. Together with improvements
in clinical care for dengue patients and better understanding of
Symptomatic
dengue-infected
n=192 (%)
Inapparent
dengue
infection
n=29 (%) Crude OR 95% CI P* Adjusted OR 95% CI P
NS1 antigen
Negative 21 (10.9) 23 (79.3) 1 1
Positive 171 (89.1) 6 (20.7) 0.03 [0.01–0.1] ,0.0001 0.05 [0.01–0.2] ,0.0001
*Potential confounders with a P value of less than 0.20 in univariate analysis were retained for the final multivariable analyses. In this table: weight-based Z-score,
platelets, neutrophils, lymphocytes, monocytes, ASAT, ALAT and NS1 antigen.
aASAT: Aspartate amino transferase.
bALAT: Alanine amino transferase.
Univariate and multivariable logistic regression were used for analyses.
doi:10.1371/journal.pntd.0001482.t004
Table 4. Cont.
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antiviral drugs would complete the arsenal of weapons for
combating dengue worldwide.
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